Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Health and Human Services Food and Drug Administration [Docket No. FDA-2023-N-4259]
 AGENCY: Food and Drug Administration, HHS.
 ACTION: Notice.
 SUMMARY: The Food and Drug Administration (FDA, the Agency, or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
 DATES: Submit written comments (including recommendations) on the collection of information by April 1, 2024.
 ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be submitted to 
                        *https://www.reginfo.gov/​public/​do/​PRAMain.*
                         Find this particular information collection by selecting “Currently under Review—Open for Public Comments” or by using the search function. The OMB control number for this information collection is 0910-0498. Also include the FDA docket number found in brackets in the heading of this document.
 FOR FURTHER INFORMATION CONTACT: Rachel Showalter, Office of Operations, Food and Drug Administration, Three White Flint North, 10A-12M, 11601 Landsdown St., North Bethesda, MD 20852, 240-994-7399, 
                        *PRAStaff@fda.hhs.gov.*


SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance. Export Certificates for FDA Regulated Products OMB Control Number 0910-0498—Revision This information collection supports the implementation of FDA statutory and regulatory provisions and related forms. Sections 801(e) and 802 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 381(e) and 382) pertain to the export of FDA-regulated products and are intended to ease restrictions on exportation. The provisions also require the Agency to issue written export certifications within 20 days of any request. To offset Agency resource expenditures for processing certifications requests, the statute provides that FDA may charge firms a fee not to exceed $175. The information collection contains FDA forms (Form FDA 3613, 3613a, 3613b, 3613c, 3613f, and 3613g) related to exporting FDA-regulated products. A description of each form is provided in table 1. Table 1—Certificates and Uses
Type of certificate/Form FDA#
UseForm FDA 3613: “Supplementary Information Certificate to Foreign Government Requests”
                             “Exporter's Certification Statement Certificate to Foreign Government” 
                             “Exporter's Certification Statement Certificate to Foreign Government (For Human Tissue Intended for Transplantation)”
For the export of products legally marketed in the United States.Form FDA 3613a: “Supplementary Information Certificate of Exportability Requests”
                             “Exporter's Certification Statement Certificate of Exportability”
For the export of products not approved for marketing in the United States (unapproved products) that meet the requirements of sections 801(e) or 802 of the FD&C Act.Form FDA 3613b and Form FDA 3613f: “Supplementary Information Certificate of a Pharmaceutical Product”
                             “Exporter's Certification Statement Certificate of a Pharmaceutical Product”
Conforms to the format established by the World Health Organization and is intended for use by the importing country when the product in question is under consideration for a product license that will authorize its importation and sale or for renewal, extension, amending, or reviewing a license.Form FDA 3613c: “Supplementary Information Non-Clinical Research Use Only Certificate”
                             “Exporter's Certification Statement (Non-Clinical Research Use Only)”
For the export of a non-clinical research use only product, material, or component that is not intended for human use and which may be marketed in, and legally exported from the United States under the FD&C Act.Form FDA 3613g: “Certificate to Foreign Government for Devices Not Exported from the United States”
For the shipping of devices not exported from the United States that may be legally marketed in the United States.
 To obtain a fillable PDF file of each form, visit 
                    *https://www.fda.gov/​about-fda/​reports-manuals-forms/​forms,*
                     and type “3613” in the search field. We accept online applications for export certificates for specific product areas through web-based application systems. To access these web-based application systems, visit the FDA Industry Systems web page at 
                    *https://www.access.fda.gov.*
                     For additional information on export certification processing for specific product areas refer to the following websites: 
                    *https://www.fda.gov/​vaccines-blood-biologics/​compliance-actions-biologics/​exporting-cber-regulated-products,*
                     (CBER); 
                    *https://www.fda.gov/​medical-devices/​importing-and-exporting-medical-devices/​exporting-medical-devices*
                     (CDRH); 
                    *https://www.fda.gov/​drugs/​human-drug-exports/​electronic-certificates-pharmaceutical-product-general-information*
                     (CDER); and 
                    *https://www.fda.gov/​animal-veterinary/​import-exports/​exporting-animal-feed-and-animal-drugs*
                     (CVM). We are transitioning to a requirement for electronic submission of the forms related to medical device products. Therefore, we revised FDA Forms 3613, 3613a, 3613c, and 3613g to remove the paper submission instructions in the portions of the forms related to medical device products. We developed the guidance document “FDA Export Certification” (August 2021) which is intended to provide a general description of FDA export certification to industry and foreign governments. The guidance document is available from our website at: 
                    *https://www.fda.gov/​RegulatoryInformation/​Guidances/​ucm125789.htm.*
                     Agency guidance documents are issued in accordance with our good guidance practice regulations in 21 CFR 10.115, 
                    ( print page 14883)
                    which provide for public comment at any time. In the 
                    **Federal Register**
                     of October 25, 2023 (88 FR 73349), FDA published a 60-day notice requesting public comment on the proposed collection of information. No comments were received. FDA estimates the burden of this collection of information as follows: Table 2—Estimated Annual Reporting Burden 1
Forms FDA 3613, 3613a, 3613b, 3613c, 3613f, and 3613g; submission to FDA center
Number of
                             respondents
Number of
                             responses per 
                             respondent
Total annual
                             responses
Average
                             burden per 
                             response
Total hoursCenter for Biologics Evaluation and Research (CBER)
2,344
1
2,344
1
2,344Center for Devices and Radiological Health (CDRH)
11,175
1
11,175
2
22,350Center for Drug Evaluation and Research (CDER)
9,396
1
9,396
1
9,396Center for Veterinary Medicine (CVM)
1,618
1
1,618
1
1,618Total
24,533

24,533

35,7081
                         There are no capital costs or operating and maintenance costs associated with this collection of information.
 Appropriate centers within FDA review product information submitted by firms in support of the firms' certificate requests. We rely on respondents to certify their compliance with all applicable requirements of the FD&C Act both at the time the certification request is submitted to FDA and at the time the certification is submitted to the respective foreign government. Further information regarding FDA's Export Certificates may be found on our website at 
                    *https://www.fda.gov/​regulatory-information/​search-fda-guidance-documents/​fda-export-certificates.* The estimated burden for the information collection reflects an overall adjustment increase of 5,102 hours and a corresponding increase of 5,102 responses. CDER has instituted electronic certificates of pharmaceutical product (eCPP) to streamline the application process and reduce the time from receipt to issuance of export certificates. The increase in CDER export application requests is attributable to the implementation of the eCPP and an increase in drug exports. The increase is offset by a decrease in CVM and CBER export applications attributable to consequences of the COVID-19 pandemic. In addition, revised form instructions related to medical device products are included in the information collection request. Dated: February 23, 2024. Lauren K. Roth, Associate Commissioner for Policy.


[FR Doc. 2024-04155 Filed 2-28-24; 8:45 am] BILLING CODE 4164-01-P